Hi Lopez
From the SITC 2017 abstracts (O41 on pages 108/109), the BMS trial of its IDO1 & Opdivo combo resulted in 11% Grade 3/4 SAEs and another 2% discontinuation from drug toxicity (including a death) from 216 patients.
https://higherlogicdownload.s3.amaz...nual Meeting 2017/SITC_2017_Abstract_Book.pdf
So it looks like the IV Cavatak/Keytruda combo has a slightly better safety profile (& more importantly, no toxicity-related deaths !)
Cheers
Ann: New Data at SITC Meeting. Further Studies Announced, page-53
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
